细胞衰老在非酒精性脂肪性肝病及向非酒精性脂肪性肝炎进展中的作用
本文综述细胞衰老在非酒精性脂肪性肝病(NAFLD)及向非酒精性脂肪性肝炎(NASH)进展中的作用。衰老涉及端粒缩短、核区扩大及基因组和线粒体DNA损伤等改变,导致不可逆细胞周期停滞和促炎细胞因子分泌。综述还讨论新型衰老细胞溶解药物的有效性与安全性及未来待解决问题。
要点
- 细胞衰老参与NAFLD发生及向NASH进展,其特征包括炎症、肝细胞气球样变和肝纤维化。
- 衰老可能既是NAFLD/NASH的刺激因素,也是疾病的结果。
- 综述讨论了衰老细胞溶解药物延迟或治疗NAFLD/NASH的有效性与安全性。
核心结论
- 细胞衰老参与NAFLD/NASH的发病和进展,并可能既是刺激因素也是疾病结果。
- 综述总结了衰老细胞溶解药物及治疗选择的有效性与安全性,并指出未来待解决问题。
研究设计与样本
- 本文为综述,总结当前关于细胞衰老在NAFLD/NASH中影响的文献。
主要发现
- 衰老时细胞发生端粒缩短、核区扩大及基因组和线粒体DNA损伤,导致不可逆细胞周期停滞和促炎细胞因子分泌。
- 多项人类和动物研究强调衰老参与肝脂肪变性发病及向NASH进展,NASH以炎症、肝细胞气球样变和肝纤维化为特征。
- NAFLD发生及向NASH进展常伴随代谢失调和肝脏炎症现象,这些现象可能促进或源于细胞衰老。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, cellular senescence has generated a lot of interest among researchers because of its involvement in both the normal aging process and common human diseases. During senescence, cells undergo alterations that include telomere shortening, nuclear area enlargement, and genomic and mitochondrial DNA damage, leading to irreversible cell cycle arrest, and secretion of proinflammatory cytokines. Evidence suggests that the complex process of senescence is involved in the development of a plethora of chronic diseases including metabolic and inflammatory disorders and tumorigenesis. Recently, several human and animal studies have emphasized the involvement of senescence in the pathogenesis and development of liver steatosis including the progression to nonalcoholic steatohepatitis (NASH) as characterized by the additional emergence of inflammation, hepatocyte ballooning, and liver fibrosis. The development of nonalcoholic fatty liver disease (NAFLD) and its progression to NASH are commonly accompanied by several pathophysiological events including metabolic dysregulation and inflammatory phenomena occurring within the liver that may contribute to or derive from cellular senescence, implying that the latter may be both a stimulus and a consequence of the disease. Conclusion: In this review, we summarize the current literature on the impact of cellular senescence in NAFLD/NASH and discuss the effectiveness and safety of novel senolytic drugs and therapeutic options available to delay or treat the disease. Finally, we identify the open questions and issues to be addressed in the near future.
引用
- Papatheodoridi AM, Chrysavgis L, Koutsilieris M, et al. The Role of Senescence in the Development of Nonalcoholic Fatty Liver Disease and Progression to Nonalcoholic Steatohepatitis. Hepatology. 2019. PMID: 31230380. doi:10.1002/hep.30834
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。